These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 14696877)

  • 1. An overview of drug development in the United States and current challenges.
    Moore SW
    South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How are drugs approved? Part 1: the evolution of the Food and Drug Administration.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Jan; 46(1):15-9. PubMed ID: 18251347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How are drugs approved? Part 2: ethical foundations of clinical research.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Feb; 46(2):15-20. PubMed ID: 18293779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 19. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.